PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

August 5, 2024

On July 30, 2024, PepGen announced positive data from the low-dose (5 mg/kg) cohort of PGN-EDO51 in the ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for the treatment of Duchenne Muscular Dystrophy.

To read more, please click here.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open